In8Bio Inc is a biotechnology company focused on developing innovative therapies for cancer treatment
The company specializes in the advancement of cell-based therapies, particularly utilizing T cell engineering to target and eliminate cancer cells. By harnessing the power of the immune system, In8Bio aims to create effective and personalized treatment options for patients with various types of malignancies. Their research and development efforts are centered around developing cutting-edge approaches that enhance the efficacy and safety of immunotherapies, contributing to the evolving landscape of cancer treatment.
In8bio (NASDAQINAB) is developing groundbreaking treatments that use the body’s immune system to fight cancer more effectively, with a mission to provide new hope to patients facing challenging diagnoses. The company will be presenting alongside world-class headliners such as Zack Kass, former Head of Go-To-Market at OpenAI where ChatGPT was created, and “Shark Tank” stars Kevin O’Leary, Robert Herjavec, and Daymond John.
- Presented new preclinical data demonstrating proof-of-concept for non-signaling Chimeric Antigen Receptor (nsCAR) platform to effectively target cancer cells while preserving healthy tissue
NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company advancing innovative gamma-delta T cell therapies, announced today that the first patient in its Phase 2 clinical trial evaluating INB-400 in patients with newly diagnosed glioblastoma multiforme (GBM) has been successfully dosed at the Cleveland Clinic in Ohio.
NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced an oral presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, taking place May 7 – 11, 2024, in Baltimore, MD and virtually.
NEW YORK, April 16, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced that William Ho, CEO and Co-founder, will present at the Noble Capital Markets’ Emerging Growth Virtual Healthcare Equity Conference on Thursday, April 18th at 12:30pm ET.
IN8bio's nsCAR platform, INB-300. Presented at AACR 2024, new preclinical data highlights its superior selectivity in targeting leukemia cells while sparing healthy tissue. Experience a potential wider therapeutic window without compromising efficacy.
Shares of PriceSmart, Inc. (NASDAQPSMT) rose sharply in today’s pre-market trading as the company posted better-than-expected earnings for its second quarter.
